Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research interests include Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Viral-associated cancers and disorders, and CAR-T cell therapy research.
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia
Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
Genetic and phenotypic attributes of splenic marginal zone lymphoma
POLATUZUMAB VEDOTIN + RITUXIMAB + LENALIDOMIDE IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL
Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes
High total metabolic tumor volume at baseline predicts survival independent of response to therapy
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R<sup>2</sup>) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma.
Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma
ΝFΚΒΙΕ Deletions: A Novel Marker of Clinical Aggressiveness in Primary Mediastinal B-Cell Lymphoma
Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy
Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis
Molecular Subsets of Mantle Cell Lymphoma Defined by the <i>IGHV</i> Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
CCND2 rearrangements are the most frequent genetic events in cyclin D1− mantle cell lymphoma
A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma